Trial Profile
A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) [sargramostim] as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 05 Apr 2017 Results assessing changes in the circulating antigenic repertoire of prostate cancer patients treated with GM-CSF using patient data from this and other two trials (NCT00064129 and NCT00323882), presented at the 108th Annual Meeting of the American Association for Cancer Research
- 18 Jun 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 10 Oct 2012 Planned number of patients changed from 28 to 24.